Switching biologic agents for uveitis

Eye

Volumn 23, Issue 9, 2009, Pages 1868-1870

  Dhingra, N ^a   Morgan, J ^a   Dick, A D ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

Adalimumab; Biologics; Infliximab; Uveitis

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AMBLYOPIA; ANKYLOSING SPONDYLITIS; ARTICLE; CHILD; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MALE; MEDICAL RECORD REVIEW; POLYARTHRITIS; PRESCHOOL CHILD; REMISSION; RETINA MACULA CYSTOID EDEMA; SARCOIDOSIS; SCHOOL CHILD; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UVEITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; DRUG SUBSTITUTION; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; TREATMENT OUTCOME; UVEITIS;

EID: 70349200939     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.203     Document Type: Article

References (9)

1. Dick AD, Isaacs JD. Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol 1999; 83(11): 1230-1234.
2. Imrie F, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18: 481-486.
3. Hyrich KL, Lunt M, Dixon WG, Watson K D, Symmons DPM. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008; 47: 1000-1005.
4. van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007; 66: 849-851.
5. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of First International Workshop. Am J Ophthalmol 2005; 140(3): 509-516.
6. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92(4): 467-471.
7. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007; 21: 824-825.
8. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68(5): 696-701.
9. Haraoui B. Is there a rationale for switching from one antitumor necrosis factor agent to another? J Rheumatol 2004; 31: 1021-1022.